The nominal deal value is $12B. If consummated, this deal will create the second-largest global CRO, employing 35,000 people. (IQV is the largest.) A focus of the combined firm will be “virtual” clinical trials.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”